Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Conservation of Protein Domains Over Different Proteins

Conservation of Protein Domains Over Different Proteins

Protein domains are small structurally independent units that are part of a single amino acid chain. Although these domains are often structurally independent, they may rely on synergistic effects to perform their functions as part of a larger protein. Protein domains may be conserved within the same organism, as well as across different organisms.
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to form...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single-Incision Double Thoracotomy for Open Thoracoabdominal Aortic Aneurysm Repair: Case Report and New Technique.

Annals of thoracic surgery short reports·2025

Same author

Surgical Management of Type A Aortic Intramural Hematoma With Cerebral Malperfusion: Carotid Revascularization and Arch Replacement.

Annals of thoracic surgery short reports·2025

Same author

Vasoplegia and cardiopulmonary bypass: role of oxidation-reduction dysregulation as a mechanism and therapeutic target.

British journal of anaesthesia·2025

Same author

Current State of Patient Blood Management in Cardiovascular Surgery: Insights from a Survey of Leading Centers.

Journal of cardiothoracic and vascular anesthesia·2025

Same author

Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines.

JAMA·2025

Same author

Preliminary insights into monitoring bivalirudin anticoagulation: A retrospective cohort study of aPTT versus a chromogenic anti-IIa assay.

Journal of clinical anesthesia·2025

Same journal

Outcomes of donation after circulatory death heart transplantation in recipients with pulmonary hypertension.

The Journal of thoracic and cardiovascular surgery·2026

Same journal

Extending the age cutoff: Outcomes of the Ross procedure in patients older than 60 years. A two-center retrospective study from the Canadian Ross Registry.

The Journal of thoracic and cardiovascular surgery·2026

Same journal

The first prospective Safety And efFectiveness trial of the excimer laser assisted non-occlusive anastomosis system in Coronary Artery Bypass grafting.

The Journal of thoracic and cardiovascular surgery·2026

Same journal

Durability and Elongation of Artificial Chords in Pediatric Mitral Valve Repair: A Comprehensive Echocardiographic Analysis.

The Journal of thoracic and cardiovascular surgery·2026

Same journal

Prognostic Value of Aortic Height and Size Indices in Veterans with Ascending Aortic Aneurysm.

The Journal of thoracic and cardiovascular surgery·2026

Same journal

The Search for Borderline Hearts within Biventricular Repairs of Complete Atrioventricular Septal Defects.

The Journal of thoracic and cardiovascular surgery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 20, 2026

In Vivo Proximity Biotinylation for Protein Interaction Studies in Paramecium tetraurelia

In Vivo Proximity Biotinylation for Protein Interaction Studies in Paramecium tetraurelia

Published on: September 12, 2025

Aprotinin revisited.

Abe Deanda¹, Bruce D Spiess

¹Department of Cardiothoracic Surgery, NYU-Langone Medical Center, New York, NY, USA. abe.deanda@nyumc.org

The Journal of Thoracic and Cardiovascular Surgery

|July 17, 2012

Summary

This summary is machine-generated.

Aprotinin, an antifibrinolytic drug used in cardiac surgery, was withdrawn from the US market in 2008. A recent re-review of Canadian trial data suggests flaws in the original study, prompting a revisit of the aprotinin controversy.

More Related Videos

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

Published on: August 6, 2018

Refinement of OnePot PURE and Crude Ribosome Production for Reproducible Cell-free Protein Synthesis

Refinement of OnePot PURE and Crude Ribosome Production for Reproducible Cell-free Protein Synthesis

Published on: August 22, 2025

Related Experiment Videos

Last Updated: May 20, 2026

In Vivo Proximity Biotinylation for Protein Interaction Studies in Paramecium tetraurelia

In Vivo Proximity Biotinylation for Protein Interaction Studies in Paramecium tetraurelia

Published on: September 12, 2025

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

Published on: August 6, 2018

Refinement of OnePot PURE and Crude Ribosome Production for Reproducible Cell-free Protein Synthesis

Refinement of OnePot PURE and Crude Ribosome Production for Reproducible Cell-free Protein Synthesis

Published on: August 22, 2025

Area of Science:

Cardiovascular Surgery
Pharmacology
Clinical Trial Analysis

Background:

Aprotinin, an antifibrinolytic agent, was widely used in cardiac surgery to reduce bleeding and complications.
Its US market withdrawal in 2008 followed preliminary results from a Canadian clinical trial suggesting increased mortality and renal failure risks.
The drug was particularly utilized in complex or redo cardiac procedures.

Discussion:

A recent re-evaluation of the Canadian trial data has identified significant flaws in the study's design and interpretation.
These methodological issues question the validity of the initial findings linking aprotinin to adverse outcomes.
This review critically examines the historical data and the subsequent controversy surrounding aprotinin's safety and efficacy.

Key Insights:

The original Canadian trial data, leading to aprotinin's market withdrawal, has been re-analyzed.
Flaws in the study's methodology and result interpretation have been identified.
The re-review challenges the conclusions drawn about aprotinin's association with increased mortality and renal failure.

Outlook:

Further investigation into the re-analyzed data is warranted to definitively assess aprotinin's risk-benefit profile.
This could potentially inform future clinical practice guidelines regarding antifibrinolytic use in cardiac surgery.
Revisiting the aprotinin controversy may offer valuable lessons for clinical trial design and data interpretation in cardiovascular medicine.